.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,648,119

« Back to Dashboard

Details for Patent: 8,648,119

Title:Controlled release immunomodulator compositions and methods for the treatment of otic disorders
Abstract: Disclosed herein are compositions and methods for the treatment of otic disorders with immunomodulating agent compositions and formulations administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Inventor(s): Lichter; Jay (Rancho Santa Fe, CA), Trammel; Andrew M. (Olathe, KS), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Dellamary; Luis A. (San Marcos, CA), Lebel; Carl (Malibu, CA), Harris; Jeffrey P. (La Jolla, CA)
Assignee: Otonomy, Inc. (San Diego, CA) The Regents of the University of California (Oakland, CA)
Filing Date:May 26, 2009
Application Number:12/472,034
Claims:1. A method of treating an otic disease or condition selected from autoimmune ear disease, and Otitis media, comprising administering an intratympanic composition on or near the round window membrane of the ear of an individual in need thereof, the composition comprising: between about 0.01% to about 20% by weight of a multiparticulate anti TNF alpha agent or pharmaceutically acceptable salt thereof; and a copolymer of polyoxyethylene-polyoxypropylene in an amount sufficient to provide a gelation temperature of between about 19.degree. C. and about 42.degree. C., and a gelation viscosity between about 15,000 cP and about 1,000,000 cP; such that sustained release of the anti TNF alpha agent across the round window membrane into the cochlea occurs for a period of at least 5 days after a single administration.

2. The method of claim 1, wherein the multiparticulate anti TNF alpha agent is essentially in the form of micronized particles.

3. The method of claim 1, wherein the copolymer of polyoxyethylene-polyoxypropylene is Poloxamer 407.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc